Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.65 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | SGK1 | O00141 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 4/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | AXL | P30530 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757332 | 0.92 | CAMKK2 (0.67) | CAMKK2PLK4RIPK1KITSGK1 | |
| SCHEMBL4165835 | 0.87 | CAMKK2 (0.74) | CAMKK2PLK4RIPK1KITSGK1 | |
| SCHEMBL3774068 | 0.86 | TNIK (0.62) | CAMKK2RIPK1KITSGK1PIK3CA | |
| SCHEMBL3769509 | 0.84 | DYRK1A (0.64) | CAMKK2RIPK1KITSGK1PIK3CA | |
| SCHEMBL8941762 | 0.84 | CAMKK2 (0.74) | CAMKK2RIPK1KITSGK1PIK3CA | |
| SCHEMBL4171706 | 0.82 | CAMKK2 (0.61) | CAMKK2PLK4RIPK1KITSGK1 | |
| SCHEMBL8941919 | 0.80 | CAMKK2 (0.69) | CAMKK2PLK4RIPK1KITPIK3CA | |
| SCHEMBL3774334 | 0.80 | AXL (0.74) | CAMKK2PLK4RIPK1KITSGK1 | |
| SCHEMBL3770702 | 0.80 | CAMKK2 (0.74) | CAMKK2PLK4RIPK1SGK1ITK | |
| SCHEMBL3775635 | 0.80 | PIK3CA (0.72) | KITSGK1PIK3CANTRK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | CAMKK2 157/4885PLK4 29/4885RIPK1 143/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | CAMKK2 125/4885PLK4 56/4885RIPK1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.